Menu
Search
|

Menu

Close
X

Viking Therapeutics Inc VKTX.OQ (NASDAQ Stock Exchange Capital Market)

10.92 USD
-- (--)
As of Jul 20
chart
Previous Close 10.92
Open --
Volume --
3m Avg Volume 556,805
Today’s High --
Today’s Low --
52 Week High 13.40
52 Week Low 0.88
Shares Outstanding (mil) 58.43
Market Capitalization (mil) 602.45
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.86 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.078
FY17
-0.807
FY16
-0.997
FY15
-4.019
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
--
8.11
Price to Book (MRQ)
vs sector
7.66
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
5.12
17.18
LT Debt to Equity (MRQ)
vs sector
0.00
13.08
Return on Investment (TTM)
vs sector
-44.80
13.18
Return on Equity (TTM)
vs sector
-47.16
15.09

EXECUTIVE LEADERSHIP

Lawson Macartney
independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Brian Lian
President, Chief Executive Officer, Director, Since 2015
Salary: $440,000.00
Bonus: --
Michael Morneau
Chief Financial Officer, Since 2014
Salary: $300,000.00
Bonus: --
Matthew Foehr
Director, Since 2014
Salary: --
Bonus: --
Charles Rowland
Independent Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

12340 El Camino Real Ste 250
SAN DIEGO   CA   92130-3093

Phone: +1858.7044660

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

SPONSORED STORIES